Maple Syrup Urine Disease

Definition And Genetics

Maple Syrup Urine Disease is an autosomal recessive inborn error of branched-chain amino acid (BCAA) metabolism.
The disorder is caused by a deficiency of the mitochondrial Branched-Chain $α$ -Ketoacid Dehydrogenase (BCKDH) complex.
The BCKDH complex catalyzes the oxidative decarboxylation of branched-chain $α$ -ketoacids and consists of three catalytic components ( $E_{1}$ , $E_{2}$ , and $E_{3}$ ).
Genetic defects involve specific subunits: BCKDHA ( $E_{1 α}$ ) and BCKDHB ( $E_{1 β}$ ) account for ~80% of cases, DBT ( $E_{2}$ ) accounts for ~20% of cases, and DLD ( $E_{3}$ ) is rare.

The enzymatic defect results in the systemic accumulation of BCAAs (Leucine, Isoleucine, and Valine) and their corresponding $α$ -ketoacids.
Leucine is the primary neurotoxin; acute massive elevations cause cerebral edema, while chronic elevations lead to hypomyelination.
Excess Leucine competitively saturates the Large Neutral Amino Acid (LNAA) transporter at the blood-brain barrier.
This competition inhibits the cerebral uptake of other essential amino acids, resulting in severe depletion of neurotransmitters (dopamine, serotonin) and impaired cerebral protein synthesis.
The accumulated leucine metabolite, α-Ketoisocaproic Acid (KIC), directly inhibits the Krebs cycle and oxidative phosphorylation, precipitating cellular energy failure.
High KIC levels also inhibit the pyruvate dehydrogenase and $α$ -ketoglutarate dehydrogenase complexes, resulting in defective oxidative phosphorylation and subsequent cerebral lactate accumulation.

Classification	Enzyme Activity	Onset & Clinical Presentation
Classic MSUD	<2-3%	Neonatal onset (4–7 days). Presents with poor feeding, lethargy, alternating hypertonia/hypotonia, opisthotonos, and pathognomonic “boxing and bicycling” movements. Progresses to coma and central respiratory failure if untreated.
Intermediate MSUD	3–30%	Insidious onset in infancy/childhood. Features failure to thrive, seizures, and chronic intellectual disability. Catabolic stress can trigger acute encephalopathy.
Intermittent MSUD	5–40%	Normal growth with asymptomatic intervals. Acute metabolic decompensations triggered by catabolic stress (infection, surgery).
Thiamine-Responsive	Variable	Rare variant often due to DBT mutations. Hyperleucinemia improves with high-dose Thiamine (10-100 mg/day).
E3 Deficiency	Rare	Combined phenotype of MSUD with profound lactic acidosis and Leigh syndrome-like presentation.

A characteristic sweet, malty, “maple syrup” or “burnt sugar” odor is noted in cerumen first, followed by urine and sweat, due to the accumulation of sotolone.

Newborn Screening (NBS): Tandem Mass Spectrometry (TMS) detects elevated Leucine/Isoleucine and the presence of Alloisoleucine.
Plasma Amino Acids: Reveals markedly elevated Leucine, Isoleucine, and Valine alongside decreased Alanine.
Alloisoleucine: The presence of Alloisoleucine in plasma is pathognomonic for MSUD.
Urine Organic Acids: Demonstrates elevated branched-chain $α$ -ketoacids and hydroxyacids.
DNPH Test: The addition of 2,4-dinitrophenylhydrazine to urine yields a characteristic yellow precipitate, serving as a rapid bedside screen for ketoacids.
Neuroimaging: Acute Magnetic Resonance Imaging shows restricted diffusion (cytotoxic edema) in the deep cerebellar white matter, brainstem, globus pallidus, and thalami. Chronic imaging reveals diffuse cerebral atrophy and hypomyelination.

Goal: Rapidly reduce plasma Leucine levels and reverse the catabolic state.
Dietary Arrest: Immediately cease all protein intake.
Anabolism Promotion: Administer high-calorie intravenous fluids (Glucose 10–12 mg/kg/min and Lipids) to suppress endogenous proteolysis. Insulin infusions may be required to control hyperglycemia and drive anabolism.
Toxin Removal: Hemodialysis or hemofiltration is the most effective modality and is strictly indicated if Leucine >250 mg/dL (>1900 µmol/L) or in cases of severe encephalopathy.
Amino Acid Competition: Administer enteral or intravenous Isoleucine and Valine to competitively block Leucine uptake at the blood-brain barrier and prevent secondary deficiencies.

Dietary Therapy: Requires lifelong restriction of natural protein to limit Leucine intake, alongside BCAA-free medical formulas providing essential amino acids, calories, and micronutrients.
Therapeutic Target: Maintain plasma Leucine levels between 75–300 µmol/L depending on age.
Pharmacotherapy: A standardized Thiamine trial (50–200 mg/day for 3–4 weeks) is indicated for all newly diagnosed patients.
Organ Transplantation: Liver transplantation is curative for systemic metabolic instability, protecting the patient from acute crises and allowing diet liberalization, though it does not reverse pre-existing brain damage.